Korea-US Hypertension Drug 'Amozaltan' Achieves 1 Trillion KRW in Cumulative Sales as First Domestic Single Medication

Since its launch in 2009, Hanmi Pharmaceutical's hypertension drug 'Amozantan' has surpassed cumulative sales of 1 trillion KRW. Although it is a generic combination drug rather than a pure new drug, it is significant as the first domestic prescription drug to achieve cumulative sales of 1 trillion KRW for a single product.

Hanmi Pharm's hypertension medication 'Amozaltan'
Photo by Hanmi Pharm

Hanmi Pharmaceutical announced on the 22nd that according to Ubist data, cumulative prescription sales of Amozantan from its launch in June 2009 until last year amounted to 1.0494 trillion KRW. Amozantan is a combination drug made by combining 'Amodipine,' a generic of the hypertension treatment drug 'Norvasc' (active ingredient amlodipine), and 'Ozantan,' a generic of 'Cozaar' (losartan).

Amozantan surpassed 10 billion KRW in prescription sales within six months of its release in 2009 and has maintained an average annual growth rate of 15% over the past 14 years. Last year, it recorded annual sales of 89.2 billion KRW. It is also exported to more than 50 countries overseas under the name 'CozaarXQ' through the American company Merck (MSD), which developed the original losartan drug Cozaar. This was the first case of a global pharmaceutical company introducing and selling a domestically produced finished drug.

Hanmi Pharmaceutical has expanded the 'Amozantan family' by launching 'Amozantan Plus,' a triple combination drug adding the diuretic 'Chlorthalidone'; 'Amozantan Q,' a triple combination drug adding the dyslipidemia treatment ingredient 'Rosuvastatin'; and 'Amozantan XQ,' a quadruple combination drug adding another dyslipidemia treatment ingredient 'Ezetimibe' to Amozantan Q. The cumulative sales of all these product lines amount to 1.2672 trillion KRW. Last year, Amozantan recorded sales of 89.2 billion KRW, Amozantan Plus 30.9 billion KRW, Amozantan Q 11.3 billion KRW, and Amozantan XQ 10.5 billion KRW. Notably, Amozantan XQ surpassed 10 billion KRW in sales for the first time last year.

This content was produced with the assistance of AI translation services.